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KEY POINTS
 Alternative access is used in a minority of cases and is associated with higher rates of morbidity
and mortality because of patient and technical factors.
 Transthoracic access is associated with higher rates of mortality and postprocedure atrial
fibrillation.
 A myriad of choices is available, but centers should focus on 1 to 2 techniques to optimize
proficiency in alternative access.
 Transaxillary access is popular and widely used but associated with higher rates of stroke as
compared with other alternative access techniques.

INTRODUCTION
Transcatheter aortic valve replacement (TAVR)
has rapidly become the treatment of choice as
an alternative to surgical aortic valve replacement in patients at high, intermediate, and low
procedural risk patients.1–3 Iterative advances
in technology results in increasingly lower profile
sheaths, enabling broad use of transfemoral access. Despite these improvements, alternative
access is still recommended in up to 21% of patients4 because of iliofemoral disease, tortuosity,
severe calcification, aneurysms, mural thrombus,
or previous vascular surgery, hence the
continued need for alternative access to avoid

vascular complications and their associated
morbidity and mortality.5,6 Recently, an analysis
of TAVR procedures from 2015 to 2017 revealed
that 15.3% of cases used alternative access, and
an inverse relationship between operator volume and 30-day mortality was seen in the transcatheter valve therapy (TVT) registry.7 Given the
19.45% relative reduction of 30-day mortality
between the highest and lowest volume operators, expertise is a major determinate of outcomes.7 The differential in knowledge and
experience prompts this comprehensive review
of the technique and outcomes of the following
nonfemoral artery alternative access routes:
antegrade, transapical (TA), transaortic (TAo),
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Fig. 1. Comprehensive list of nontransfemoral access previously used
to perform TAVR. abd, abdomen.

suprasternal, transaxillary (TAx), transcarotid
(TC), and transcaval (TCav) access (Fig. 1).

ANTEGRADE (TRANSSEPTAL) ACCESS
The progenitor balloon expandable valve
required using a 24F sheath, but a retrograde
delivery catheter had not yet been designed;
therefore, first-in-man TAVR used antegrade,
transseptal access (Fig. 2). The initial description
of TAVR was a 6-patient series of transseptal
antegrade transcatheter heart valve (THV) delivery by Dr Alain Cribier and colleagues in 2004.8,9
The procedure was successful in 5 patients, but
mitral valve injury prevented the widespread
adoption of the technique; TAVR did not
disseminate until the engineering of a retrograde delivery system.10,11 This technique is
seldom used, There are few with the expertise
to use antegrade access, and despite venous access for the large-bore sheath, major bleeding
occurred in nearly half of the small series.12

TRANSTHORACIC (APICAL [TRANSAPICAL]
AND DIRECT AORTIC [TRANSAORTIC])
ACCESS
First-generation Sapien valve (Edwards Lifesciences, Irvine, CA, USA) delivery systems
required 22 to 24F sheaths for transfemoral access, and transthoracic alternative access were
commonly used.

Transapical
First described by Lichtenstein and colleagues,13
TA access experienced its highest utilization during PARTNER I and the first-generation Edwards

SAPIEN commercial roll-out. TA access begins
with a limited thoracotomy, and apical exposure
is followed by horizontal mattress pledgeted suture placement surrounding the intended area of
access, typically lateral to the true apex (Fig. 3). After puncturing with an 18-gauge needle, most operators take the approach of minimizing sheath
exchanges in the heart. Following apical puncture,
the apex is cannulated with a small sheath and then
exchanged for a stiff wire in the descending aorta.
After the large delivery sheath (24–33F Ascendra
or Acendra II, Edwards Lifesciences, Irvine, CA) is
placed over the stiff wire, valve delivery ensues
(see Fig. 3). Hemostasis is achieved by first
lowering the blood pressure using rapid pacing,
sheath withdrawal, and pledget tightening with
care not to overtension the sutures. A chest tube
is left in place, and the thoracotomy is closed.
Avoid systemic hypertension and undue stress to
the repaired apex with antihypertensive medications if necessary. Apical tissue integrity is sometimes unpredictable, and cases have been
aborted because of degeneration of apical tissue
architecture or copious apical adiposity causing
ambiguity during pledget placement.
During the PARTNER I trial, 42% of patients
underwent TA access and experienced an
increased rates of in-hospital death, renal failure,
bleeding, and longer lengths of stay relative to
transfemoral procedures.12 Moreover, data
show that TA access was associated with
increased myocardial injury compared with other
access routes.14 Patients with chronic lung disease are easily compromised by apical exposure
because of thoracic pain and the presence of a
chest tube. Moreover, patients with chronic
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Fig. 2. Antegrade, transseptal TAVR performed using
an arterial-venous loop.

obstructive pulmonary disease have longer postprocedural ventilation times when treated via
TA relative to TF TAVR, indicating that TA should
be avoided in such individuals.15 The use of apical
access declined in the PARTNER II trial to 8.5%,
and a newer, smaller-caliber delivery sheath
(Ascendra II 24F) was introduced at this time.2
Although technology improved, thoracic access
(both TA and TAo) was still associated with
increased death, stroke, vascular complications,
and new atrial fibrillation (Table 1). Currently,
the Sapien 3/Ultra balloon expandable valves
(Edwards Lifesciences, Irvine, CA) use the Certitude delivery system (Edwards Lifesciences,
Irvine, CA) that has an internal diameter of 18
to 21F depending on the valve size used.
After concerns with myocardial injury and comfort with limited sternotomy or aortic cannulation,
TAo access was developed by Bapat and colleagues.16 TAo access is feasible so long as the
aorta is not excessively calcified and there is at

least 6.5 to 7 cm of length between the proposed
entry side and the aortic annulus to allow for valve
preparation. Aortic access is achieved using J-sternotomy or right lateral thoracotomy, depending
on the position of the aorta (Fig. 4). After placing
pledgeted sutures at the access site, direct puncture is performed with an 18-gauge needle (see
Fig. 4). A small sheath should be inserted to facilitate crossing the stenotic aortic valve and
exchanged for a stiff wire that enables largesheath delivery. Following THV implantation, the
pledgeted sutures are tightened for hemostatic
control and the thorax closed in the usual fashion.
Some surgeons prefer TAo over TA access
because of less surgical site pain, minimal myocardial injury, and freedom from concerns about apical tissue integrity. Rare complications of
dissections or intramural hematomas occur, and
convalescence is still prolonged.17 The use of
TAo access in the PARTNER II trial was only
3.05%,2 and US registry data show that TAo is associated with an 8% in-hospital mortality, 40% rate of
renal failure with the minority of patients able to be
discharged home (see Table 1).
Intuitively, thoracic invasion for THV implantation is less preferred. Tsuyoshi Kaneko and colleagues18 give credence to this notion by
showing higher rates of mortality, blood transfusion, atrial fibrillation, and intensive care unit
length of stay when using transthoracic access.
Moreover, new-onset atrial fibrillation is significantly increased in thoracic access, especially
TA, compared with any extrathoracic access.19
As such, transthoracic access is declining, and
TA/TAo access accounts for less than 2.8% of
all Sapien TAVR cases in the US TVT registry between 2015 and 2018.20

SUPRASTERNAL ACCESS
In 2018, Codner and colleagues21 described
suprasternal access using the dedicated Aegis

Fig. 3. TA access. (A) Surgical exposure of the myocardial apex using a soft tissue retractor and pericardial stay
stitches. Pledgeted horizontal mattress sutures have been embedded in the periapical area in preparation for apical puncture. (B) Puncture of the apex with an 18-gauge needle (arrow) and a 0.03500 J-tipped wire is inserted. (C)
An Ascendra sheath (asterisk) (Edwards Lifesciences) is advanced over a stiff wire. (D). A 26-mm Edwards Sapien
valve is implanted (double dagger).
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Table 1
Comparative results for each alternative access
Surgical
Antegrade Transaortic Transapical Axillary

Percutaneous
Axillary
Transcarotid Transcaval

In-hospital
mortality, %

0

3.4

Longer-term
mortality

7.4

4.3

22% 6 mo 19% 1 y

9% 30 d

Major
bleeding,
%

44.4

5.0

7.2

Acute kidney
injury, %

22.2

39.6

Stroke, %

0

2.5

2.8

3

6.1

4.2

5

0.5

3.8

2

2.5

1.5

13

Vascular
33.3
complications,
%

8.1

2.5

4

2.9% 30 d 5.4% 30 d
20% 1-y

4.3% 30 d

8% 30 d

NA

0.1

12

0.5

NA

12

Abbreviation: N/A, not applicable.

metallic frame (Aegis Surgical, Dublin, Ireland).
Using a 3-cm transverse incision superior to the
sternal notch, blunt dissection is performed to
expose the plane between the brachiocephalic
artery and innominate vein. The Aegis device
optimized exposure and illumination to facilitate
insertion of purse-string sutures by way of
thoracic port instruments. Once prepared, the
brachiocephalic artery is accessed with a pericardiocentesis needle to enable eventual exchange
for a delivery sheath. Postvalve implantation, a
long knot-tying instrument achieves hemostasis.
The published data consist of 11 patients with
earlier ambulation and shorter hospitalizations
that propensity matched TA or TAo. Further
studies are needed on this access route to determine generalizability of suprasternal access.

TRANSAXILLARY ACCESS
TAx access has long been used as an alternative
access for TAVR, beginning with surgical exposure for sheath insertion, and it has now evolved
to complete percutaneous access and hemostasis. Initially disseminated as an alternative access
for Medtronic Corevalve implantation,22 it has
become the dominant alternative access in the
United States.20 Advantages of axillary access
is the relative lack of atherosclerosis compared
with femoral vessels, accessibility, and extrathoracic location. The medial section of the subclavian artery is thinner with a higher proportion
of elastic fibers compared with the femoral artery, causing concern that the artery may be
fragile. Another caveat is the proximity of the
brachial plexus to the vessel and potential for

Fig. 4. TAo access. (A) Surgical TAo exposure and insertion of an 8F sheath (arrow) in the ascending aorta. (B)
Insertion of a 20F sheath (asterisk) in the ascending aorta (AA). (C) A 29-mm Sapien XT valve is implanted (double
dagger). RA, right atrium.
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Fig. 5. Axillary artery anatomy relevant to transcatheter access. Angiogram of the axillary artery, its 3
divisions and side branches.

compromising the upper extremity via peripheral nerve injury or distal embolism.23
The axillary artery is divided into 3 segments
(Fig. 5), with the most proximal section between
the lateral margin of the first rib and medial
border of the pectoralis minor muscle. The second segment is deep to the pectoralis minor
muscle, whereas the third segment is between
the lateral border of the pectoralis minor and
inferior border of the teres major muscle.
Computed tomographic analysis shows that the

axillary artery is usually on average 1.5 mm
smaller than the corresponding lower-extremity
vessels.24 Occasionally, a pacemaker or implantable cardioverter defibrillator encroaches on the
deltopectoral groove, crowding the access
point. In addition, large-bore axillary access
should be avoided in the presence of an ipsilateral patent mammary graft to prevent ischemia
during cannulation.
Operators should aim to access the distal end
of the first segment or proximal second segment

Fig. 6. Percutaneous axillary access for TAVR. (A) Combined use of fluoroscopic subtraction to outline the vessel
and ultrasound (asterisk) to access the axillary artery using a 21-gauge needle and 0.01800 wire (arrow). (B) “Preclose” of the axillary artery using a Proglide Perclose (triangle) (Abbott Vascular, Santa Clara, CA). (C) Exchange
for a 14F E-Sheath (dagger) (Edwards Lifesciences, Irvine, CA) over a stiff wire. (D) Balloon tamponade (double
dagger) of the vessel postsheath removal and tightening of the Perclose sutures. (E) Completion angiogram
showing no evidence of dissection or extravasation.
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Fig. 7. TC TAVR. (A) Surgical exposure of the carotid artery (arrow). (B) Insertion of a 9F sheath in the carotid artery
using the Seldinger technique (triangle). (C) Crossing the aortic valve using a JR4 catheter (dagger). (D) Exchanging
for a 14F E-sheath (double dagger). (E) Delivery of a 26-mm Edwards Sapien 3 Ultra valve. (F) Completion angiography of the left carotid access site demonstrating no dissection or extravasation.

at a shallow angle to avoid sheath kinking
(Fig. 6). The left axillary artery is more commonly
used. Take care to avoid damaging the subclavian artery, as surgical rescue of this
vessel requires a sternotomy. In preparation for
large-bore TAVR access, the authors’ center
routinely prepares the ipsilateral radial artery
with a 7F sheath and a 0.014 to 0.01800 wire for
endovascular management and rescue. Using a
combination of fluoroscopy and ultrasound, the
axillary artery is punctured and dilated, and Proglide sutures are implanted in typical fashion
before large-sheath insertion (see Fig. 6).
Balloon tamponade between sheath exchanges
minimizes blood loss, and the large-bore sheath

should be inserted over a stiff wire. External
compression against the second rib is feasible
to maintain hemostasis in the case an ipsilateral
peripheral arterial access is unavailable.25
Following THV implantation, balloon tamponade
prevents bleeding and facilitates hemostasis.
Tightening of the Perclose sutures accompanied
by short duration balloon tamponade should be
sufficient for hemostasis. Given the torsion
encountered by the axillary artery, flexible selfexpanding or balloon expandable covered
stents (VBX; Gore Medical, Flagstaff, AZ, USA)
should be used for rescue; the latter in particular
is advantageous because of its large range and
ability to fit through a 7F sheath.
Fig. 8. Pathophysiology of an iatrogenic aortic-caval fistula. (A) Intuitively, most would believe that
patients should exsanguinate (red arrows) from a rent in the aorta. (B)
Because a breach is present in both
the aorta and vena cava and the
interstitial pressure of the retroperitoneal space exceeds the venous
pressure, blood preferentially shunts
from the aorta to the vena cava
(straight red arrows). Permission
received from Springer Publishing.42
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Box 1
Computed tomography for planning
transcaval access rationale and caveats
Objective: Identify a calcium-free crossing
target
Rationale: A heavily calcified aorta cannot be
traversed, and a window must be large enough
to accommodate the intended sheath. The
window should be larger than the outer
diameter of the sheath in at least 1 dimension.
Example: 18F sheath for Medtronic Evolut R
7 mm
14 to 16F e-sheath for Edwards Sapien 3 7.6
to 8.6 mm
Objective: Identify high-risk anatomy for cavalaortic traversal and large sheath insertion
Rationale: Several extravascular and
intravascular anatomic variations have been
identified that jeopardize safe traversal
Interposed structures: Arterial branches,
interposed bowel, and major veins (eg, renal)
cannot be traversed for obvious reasons
Pedunculated atheroma: Pedunculated aortic
atheroma may embolize during catheter or
closure device manipulation
Abdominal aneurysms: Ectasia and aneurysms
are not contraindications, but the large size of
the aorta may makes endovascular bailout
challenging
Dissections: Chronic dissections can extend
with large-bore sheath insertion and should be
avoided
Leftward aorta: Aortas with a cephalad leftward
trajectory may result in a tangential trajectory if
a sheath is inserted and in leftward translation
of the abdominal aorta while crossing. 20
leftward aortas should be avoided
Prior device implants: IVC filters, polyester
aortic grafts, and even pacemakers have
impeded TCav access. Although crossing an
aortic graft is possible, it should be performed
in experienced centers.
Objective: Identify vascular structures at risk
during closure of possible endograft rescue
Rationale: The crossing site should be at least
15 mm away from the aortoiliac bifurcation and
renal arteries. Important vessels, including
accessory renal arteries and lumbar collaterals,
in patients with important iliac disease should
be noted, as endograft implantation will
compromise these branches
Objective: Select preferred iliofemoral access
for possible endograft insertion
Rationale: Endograft implantation at minimum
requires a vessel that accepts a 12F access.

Should femoral arterial access be inadequate,
then the patient will require appropriate
risk:benefit counseling if operators decide to
proceed
Objective: Perform measurements for
equipment selection and corresponding bony
landmarks for crossing plan
Rationale: Once a safe traversal point has been
determined, measurements for selecting a
snare, guide, and bail-out equipment
Key findings include the following:
 Crossing site(s) and correlating lumbar
spinous level for crossing
 Distance from femoral vein puncture site to
crossing site
 Distance from aortoiliac bifurcation
 Distance from renal arteries
 Abdominal aorta size at the crossing,
30 mm cephalad and 30 mm caudad
Aortocaval distance does not appear to be
important
Permission received from Springer.

TAx access has catapulted to the most
frequently used alternative access in the United
States due to high rates of technical success
and its extrathoracic nature. Retrospective
studies have shown similar procedural outcomes
between TF and TAx routes,22,26 but most of
these data originate from self-expanding valves
and include the surgical cutdown technique. A
single-center
study
reporting
balloonexpandable platforms using TAx access reported 100 cases of complete percutaneous access with favorable outcomes.27 Analysis of the
US TVT showed that TAx access has been used
in 2% of Sapien TAVR cases.20 The
device success rate was 97.3% and was accompanied by a major vascular complication rate of
2.5%. Propensity-matched analysis demonstrated that TAx access has lower 30-day mortality, shorter intensive care unit and hospital
length of stay, but a higher stroke rate (6.1%
TAx vs 3.1% transthoracic) compared with transthoracic alternative access (see Table 1). More
recently, a 75-patient prospective registry using
ACURATE-Neo valves (Boston Scientific, Natick,
MA, USA) observed a high rate of complete
percutaneous access (90.5%) and conscious
sedation (95.2%).28 Need for bail-out stenting
and surgical vascular repair were 9.3% and 4%,
respectively, and only 1 (1.3%) cerebral vascular
event was reported.
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Right axillary access is feasible, and additional
technical challenges are encountered. No data
exist for whether the right or left axillary artery
is better for access, but the left more closely resembles the haptics of transfemoral access, and
achieving coaxial alignment is easier.29 Medtronic recommends against using Evolut (Medtronic, St. Paul, MN, USA) valves via the right
axillary artery in root angles greater than 30 ,
whereas Sapien valves can be delivered but
with some technical modifications.29 Notably,
inserting the sheath tip beyond the aortic valve
to predilate, passively exposing the valve/delivery system in the ascending aorta and flexing
the Commander delivery system (Edwards Lifesciences) away from the aortic valve will improve
coaxial alignment.

TRANSCAROTID ACCESS
Superficial location, sturdy constitution, and
deep surgical experience with the carotid artery
increased its profile as a safe access for TAVR
(Fig. 7). Achieved through surgical carotid exposure and establishing proximal and distal control
of the vessel with tourniquets, the vessel is usually accessed near the level of the thyroid cartilage. After small sheath insertion, the stenotic
aortic valve is crossed and exchanged for a stiff
wire, allowing large-bore sheath exchange (see
Fig. 7). Following THV implantation, the sheath
is withdrawn, and hemostatic control is maintained by tightening the tourniquets. Meanwhile, surgical repair of the arteriotomy can be
performed in standard fashion. Initial series of
TC access used a vascular shunt to maintain

Fig. 9. Stereotypical case of TCav access and closure. (A) Scout angiogram using DSA of the abdominal aorta in
the coplanar view. (B) A 6F IM (asterisk) guide is oriented in the IVC pointed toward the abdominal aorta. A 6F JR4
guide with a 25-mm Gooseneck snare (arrow) oriented orthogonally to the coplanar angle in preparation for wire
crossing. (C) The image intensifier is rotated 90 to the coplanar angle and the IM catheter trajectory into the open
snare in the abdominal aorta. (D) Assembly of a coaxial, serial telescoping system composed of a 0.01400 Confianza
Pro 12 within a 0.01400 Piggyback, all nested inside a 0.03500 NAVICROSS. (E) The end of the of Confianza Pro 12
wire is clamped to an electrosurgical pencil with a hemostat. (F) With the application of 50 W of “cut” electrosurgical energy, the 0.01400 wire (arrow) traverses the IVC and abdominal aortic wall to the level of the snare. (G) The
0.01400 wire is captured and towed to the thoracic aorta. A 0.01400 Piggyback catheter (circle) crosses into the
abdominal aorta. (H) Using the Piggyback 0.014” / 0.03500 wire converter enables passage of a 0.03500 NAVICROSS (arrow) to facilitate delivery of a 0.03500 wire from the IVC into the abdominal aorta. (I) With the support
a 0.03500 Lunderquist wire, a 14F Edwards Lifesciences E-sheath (arrow) is delivered to the abdominal aorta. (J) Using a small curl Agilis catheter (asterisk), an Amplatz Duct Occluder 10/8 (arrow) is deployed with the retention disc
against the abdominal aortic wall. (K) Final DSA aortogram demonstrating minimal flow (type 0) across the TCav
fistula. Permission received from Springer Publishing.42
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antegrade flow but has largely been abandoned.30 Current practice at the authors’ institution is contralateral carotid and circle of Willis
screening for advanced atherosclerosis, but this
is not a universal practice. Although traditionally
TC access has been under general anesthesia,
data from France31 suggest feasibility of TC
TAVR using local and conscious sedation and
noted that it was associated with lower stroke
rates and less days in the hospital without
compromising clinical outcomes.
Retrospective French registry data32,33 show
that TC access is associated with better outcomes compared with thoracic access; lower
incidence of atrial fibrillation, less bleeding,
acute kidney injury, and shorter hospital length
of stay. US TVT data corroborated these outcomes and observed 0.4% rate of utilization in
Sapien TAVR cases (see Table 1).20 Compared
with TAx TAVR,34 TC TAVR has similar mortalities, less fluoroscopy and procedure time, and
numerically lower stroke rates (nonstatistically
significant), making it a favorable alternative access (see Table 1).

TRANSCAVAL ACCESS
A translational to catheterization laboratory
innovation, TCav is the least conventional alternative access. First validated in an animal model,
the technique of harnessing electrosurgical power to traverse the inferior vena cava (IVC)
wall, retroperitoneal space, and abdominal
aortic wall seems counterintuitive. At first
glance, creating a vascular breach into the retroperitoneal space results in exsanguination, but
because the interstitial hydrostatic pressure of
the abdomen exceeds IVC pressure, arterial
blood preferentially shunts into the IVC. Successful use of TCav hinges on this concept, and
the IVC must serve as a sink for arterial blood
(Fig. 8).
TCav access planning requires detailed analysis of the IVC/aorta to determine the crossing
level, calcification, aortic size, distance from
renal arteries (accessory renal arteries), distance
to the iliacs, coplanar crossing angle, presence
of interposed structures, and distance from the
femoral vein (Box 1).35,36

Performing Transcaval Access
First, proper patient consent for alternative access and all necessary equipment for crossing,
closure, and bailout should be assembled
(Fig. 9). Attach the electrosurgical pad with
care not to be close to any metallic implants
(eg, hip replacement). Choose the largest

femoral artery for access in case of the need
for endovascular bailout. After vascular access,
anticoagulate with a goal of activated clotting
time of greater than 250 seconds. Perform a
scout abdominal aortogram under digital subtraction angiography (DSA) at w32 cm
Box 2
Equipment for transcaval access, closure, and
bleeding management
Transcaval access
 Electrosurgical unit and pen (Bovie)
 6F Judkins right guide
 Amplatz Gooseneck snares (w5 mm larger
abdominal aortic diameter; Medtronic)
(example: 20 mm diameter, use a 25-mm
snare) (Medtronic, St Paul, MN)
 6 to 7F Renal Double Curve-1 guide catheter
or 6 to 7F IM guide catheter (renal length)
 0.01400 microcatheters:
0.01400 Finecross 135 cm (Terumo, Ann
Arbor, MI, USA)
0.014” Piggyback 120 or 150 cm (Teleflex
Medical, Morrisville, NC, USA)
0.014” Advance Microballoon 150 cm
(Cook Medical, Bloomington, IN, USA)
 0.03500 catheters:
0.03500 CXI catheter 90 cm (Cook Medical)
0.03500 NAVICROSS catheter 90 cm
(Terumo, Ann Arbor, MI, USA)
0.03500 Lunderquist Wire (Cook Medical,
Bloomington, IN)
 0.01400 crossing wires
0.01400 Astato XS 20 wire 300 cm (Asahi
Intecc, Tustin, CA, USA)
0.01400 Confianza Pro 12 300 cm (Asahi
Intecc)
Transcaval closure:
 Small curl Agilis (Abbott Structural, Santa
Clara, CA)
 Amplatz Duct Occluder I 8/6 mm or 10/8 mm
(Abbott Structural)
 0.01400 Balance Middle Weight 300 cm
Bleeding complication rescue:
 Reliant Aortic Occlusion Balloon (Medtronic)
 Coda Aortic
Medical)

Occlusion

Balloon

(Cook

 14 to 28  45 mm Endologix Ovation iX Iliac
Limb Extender stents (Endologix, Irvine, CA)
Permission received from Springer Publishing.42
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magnification using the coplanar angle preidentified. Afterward, exchange the pigtail catheter
for a 6F JR4 guiding catheter and position a
single-loop snare (Amplatz Gooseneck; Medtronic) in the abdominal aorta at the proposed
crossing point, oriented toward the IVC. Next,
the crossing catheter, usually a 6 to 7F Renal
Double Curve or renal length internal mammary
(IM) catheter is aimed at the snare at the corresponding lumbar spinous level in the IVC. Prepare a 0.01400 Astato 20 wire, 0.01400
microcatheter, and 0.03500 braided catheter as
a serial telescoping crossing system. After
crossing the system assembly, clamp the
0.01400 wire to the electrosurgical pencil and
confirm coaxial trajectory of the wire to the snare
center using orthogonal projections (see Fig. 8).
Once confirmed, advance the wire while
applying a short burst of 50 W of electrosurgical
cutting, halting when the wire approximates the
snare location. Close the snare around the wire
and drag the 0.01400 wire cephalad to the
thoracic descending aorta. Using the countertraction of the captured wire, advance the
0.01400 catheter and 0.03500 catheter in a telescoping fashion. Release the snared 0.01400
wire to exchange for the 0.03500 Lunderquist
wire. Finally, exchange the small venous sheath
for the large-bore sheath under high-resolution
radiography to ensure smooth passage and scrutinize for sheath splaying.
Difficulty crossing should trigger caution and
prompt troubleshooting steps. First, avoid wire
buckling, as spring release of a buckled wire
may create a slitlike orifice that is unmatched
on the caval side and increase risk for bleeding.

Unexplained hemodynamic changes in the
context of multiple crossing failures should
prompt aorta angiography. Review that electrosurgical monopolar cutting of at least 50 W is being activated and the contact point between the
coronary wire and electrosurgical pencil is clean.
Several failed traversal attempts will char the
wire, necessitating replacement. If a different
crossing location is selected, knowledge of
lumen size, interposing structures, proximity to
vessels, and coplanar angles must be reassessed. The aortic wall may sometimes be resistant to catheter crossing despite wire traversal,
in which case use a 2.5- to 3.0-mm noncompliant
coronary balloon to facilitate traversal.

Transcaval Access Closure
Once the THV is implanted, reaffirm all access
emergency bailout equipment is assembled
(Box 2). Infuse protamine to normalize the activated clotting time and leave a 0.01400 300-cm
safety wire across the tract. Advance a small
curl deflectable catheter through the delivery
sheath, prepare a nitinol closure device, preferably an Amplatz Duct Occluder I (ADO I; Abbott
Vascular, Santa Clara, CA, USA). Withdraw the
large-bore TCav sheath close to the crossing
site and passively expose the ADO I, forming a
“ball.” Retract the TCav sheath to the IVC and
ensure the venous side is not obstructed to allow
venous decompression. Finally, form a retention
disc completely and deflect the catheter 90 and
retract the system with sufficient tension to
appose the aortic wall but avoid pulling through.
Once apposed, passively expose the remainder
of the device. Immediate angiography is important to recognize any bleeding early. Generally,

Fig. 10. Classification system of angiographic patterns in TCav closure. (A) Complete occlusion of the TCav tract
after closure (type 0). (B) Patent, funnel-shaped fistula (circle) flowing into the IVC (type 1). (C) Patent fistula with a
“cruciform” pattern of contrast flow (arrow) at the occluder (type 2). (D) Extravasation (arrow). Note that there is
superimposed flow into the vena cava but the contrast staining pattern without clearance should be interpreted
as retroperitoneal bleeding. Permission received from Springer Publishing.42
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there are 4 patterns of closure (Fig. 10):
Occluded (type 0), funneled (type I), cruciform
(type II), and extravasation (type III).37 Types
0 to 2 can be observed without intervention,
and extravasation requires intervention. Transient blood pressure drops of 10 to 15 mm Hg
are typical with shunting. If hypotension persists,
consider oblique views to exclude extravasation.
In the event of extravasation, rapidly exchange for an aortic occlusion balloon and tamponade the TCav tract. Occlusion of the tract
for 3- to 5-minute cycles can be done several
times, but if there is no improvement, then proceed with covered stent implantation. In rare
occasions, patients with right ventricular cardiomyopathy can experience hemodynamic embarrassment from the inability to accommodate
aortic-caval shunting. To manage extravasation
or arterial-venous shunting, occlusion of the
tract using a covered stent is sometimes necessary. A self-expanding covered stent 10% to
20% larger than the aortic lumen is recommended, and the stent of choice is an Ovation iX
aortic limb extender stent (Endologix, Irvine,
CA, USA); however, a balloon expandable stent
(VBX; Gore Medical) has been successfully used
as well.
The feasibility of this access was demonstrated in preclinical work on animals38 and subsequently performed in a series of 25 patients
without femoral or another alternative access
options.39 A larger prospective study40 was
done and reported data on 100 patients at 17
centers with 99% successful TCav access (1 failure to cross), and 98% device success (no death
or surgery bailout). The 1-year data on TCav
tract closure were reported in 2019 and showed
that 93% of patients had complete closure of the
cavoaortic tract at 1 year.41

SUMMARY
Vascular access complications continue to negatively impact patients, and alternative access remains essential to treating complex cases of
valvular heart disease. The infrequent use of
alternative access requires that operators
concentrate their focus on developing expertise
with 1 to 2 techniques or refer patients to experienced tertiary centers. Although THV evolution
may eventually further reduce the need for alternative access, high prevalence of advanced age,
morbid obesity, peripheral vascular disease, and
earlier onset diabetes will likely preserve the
need for nonfemoral access. Furthermore, the
authors’ center promotes the philosophy that
the best access be pursued in each individual

case and not simply the most convenient. To
this end, alternative access remains central to
building a high-quality tertiary center for TAVR.
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